Immunome, Inc.IMNMNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 3.21% |
| Q3 2025 | 21.61% |
| Q2 2025 | 9.71% |
| Q1 2025 | -23.01% |
| Q4 2024 | 28.74% |
| Q3 2024 | 27.91% |
| Q2 2024 | 89.23% |
| Q1 2024 | 59.48% |
| Q4 2023 | 152.08% |
| Q3 2023 | -33.12% |
| Q2 2023 | 46.08% |
| Q1 2023 | -7.97% |
| Q4 2022 | -18.62% |
| Q3 2022 | -8.61% |
| Q2 2022 | -29.23% |
| Q1 2022 | 84.22% |
| Q4 2021 | -2.84% |
| Q3 2021 | 39.59% |
| Q2 2021 | 63.37% |
| Q1 2021 | 7.85% |
| Q4 2020 | 11.62% |
| Q3 2020 | -13.11% |
| Q2 2020 | -10.54% |
| Q1 2020 | -13.03% |
| Q4 2019 | 8.86% |
| Q3 2019 | 7.48% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |